Boehringer Ingelheim GmbH 보도자료
3 out of 4 people with symptomatic asthma report reduced productivity at work
05월 27일 13:05
Not for distribution to UK/US/Canadian media Results were released today by Boehringer Ingelheim from an international survey, providing new insight into the nega...
IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease
05월 25일 11:00
Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn’s disease with investigational biologic, ...
Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
05월 23일 17:50
Boehringer Ingelheim and BioMed X announced today that they have established a new research team of outstanding scientists from around the world that will conduct re...
South Korea is first to approve next generation lung cancer treatment olmutinib (BI 1482694 / HM61713)
05월 18일 12:05
Olmutinib* (BI 1482694 / HM61713) has been approved in South Korea for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor...
New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Broad Range of Patients with IPF
05월 17일 17:30
New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in i...
Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain
05월 12일 14:15
Boehringer Ingelheim will undertake the first prospective, randomised controlled study of a non-vitamin K antagonist oral anticoagulant (NOAC) in patients with blood...
Boehringer Ingelheim: Nine out of 10 AF patients are concerned about stroke and many want to be part of OAC treatment decisions, new international survey shows
05월 11일 18:35
Nine out of 10 patients with atrial fibrillation (AF) surveyed were concerned about the risk of a stroke.[1] Oral anticoagulant (OAC) treatments are usually prescrib...
LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma
05월 09일 17:05
Boehringer Ingelheim today announced the enrolment of the first patient in the global Phase III trial evaluating the efficacy and safety of nintedanib in combination...
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
04월 20일 14:15
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced plans to conduct two outcome trials investigating the diabetes medicine Jardiance® (empagli...
Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced NSCLC published in The Lancet Oncology
04월 13일 16:30
Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-...
The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids
04월 08일 16:35
Boehringer Ingelheim today announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and m...
Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung
04월 07일 16:50
Boehringer Ingelheim today announced that the European Commission (EC) has granted marketing authorisation for Giotrif® (afatinib) for the treatment of patients with...
Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations
04월 04일 16:40
Boehringer Ingelheim has announced the results of a new interim analysis of data from the ongoing phase III RE-VERSE AD™ patient study that showed a single 5g dose o...
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
03월 24일 10:50
Boehringer Ingelheim today announces the enrollment of the first patient in RE-COVERY DVT/PE™, a global observational study on the management of blood clots in the l...
New Analyses: Adding SPIRIVA® Respimat® Effective for Uncontrolled Asthma - Regardless of Allergy Subtype[1,2,3]
03월 08일 18:00
Boehringer Ingelheim today announced the presentation of new post-hoc analyses that show the addition of SPIRIVA® (tiotropium) Respimat® to other asthma maintenance ...
1 2 3 4 5 6 7 8 9 10 11 >
Boehringer Ingelheim GmbH
상장여부 : 비상장
본사 소재지 : INGELHEIM, Germany
업종: 건강-제약
기업 개요:
등록된 회사소개가 없습니다.